Luspatercept in patients with lower-risk myelodysplastic syndromes

Luspatercept in patients with lower-risk myelodysplastic syndromes

<p><strong>Background:</strong><br /> Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds tra...

Full description

Bibliographic Details
Main Authors: Fenaux, P, Platzbecker, U, Mufti, GJ, Garcia-Manero, G, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Cazzola, M, Ilhan, O, Sekeres, MA, Falantes, JF, Arrizabalaga, B, Salvi, F, Giai, V, Vyas, P, Bowen, D, Selleslag, D, DeZern, AE, Jurcic, JG, Germing, U, Götze, KS, Quesnel, B, Beyne-Rauzy, O, Cluzeau, T, Voso, M-T, Mazure, D, Vellenga, E, Greenberg, PL, Hellström-Lindberg, E, Zeidan, AM, Adès, L, Verma, A, Savona, MR, Laadem, A, Benzohra, A, Zhang, J, Rampersad, A, Dunshee, DR, Linde, PG, Sherman, ML, Komrokji, RS, List, AF
Format: Journal article
Language:English
Published: Massachusetts Medical Society 2020

Similar Items